Nodus oncology is developing first and best-in-class molecules inhibiting novel targets within the DNA damage response and replication stress response. Supported by most recent scientific advances, we are developing the next wave of cancer therapeutics in the DNA damage response (DDR) area. Founded by Cumulus Oncology and in partnership with the Lead discovery Center, Nodus Oncology is developing an innovative portfolio focused on synthetic lethality and collateral vulnerabilities in molecularly defined cancer patient populations
Location: United Kingdom, Scotland, Edinburgh
Employees: 1-10
Total raised: $2.9M
Founded date: 2022
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.02.2023 | Seed | $2.9M | - |
Mentions in press and media 4
| Date | Title | Description |
| 08.03.2023 | DIGIT Deal Roundup | February 2023 | Welcome to the latest edition of the DIGIT Deal Roundup column, featuring some of the top investment, acquisition and expansion news stories from February, 2023. Scotland’s digital technology sector saw a number of notable deals across the ... |
| 07.02.2023 | Edinburgh BioTech Nodus Oncology Secures £2.4m Funding | Nodus Oncology, a biotech company based in Edinburgh, announced it has raised £2.4 million from new investor KHAN Technology Transfer Fund I (KHAN-I) as well as Cumulus Oncology. The company is focused on developing molecules that inhibit n... |
| 07.02.2023 | Nodus Oncology Raises £2.4M in Funding | Nodus Oncology, an Edinburgh, Scotland, UK-based biotech company focused on developing molecules that inhibit novel DNA damage response (DDR) targets, raised £2.4M in funding. The round was led by KHAN Technology Transfer Fund I and Cumulus... |
| - | Nodus Oncology | “Nodus Oncology is developing first and best-in-class molecules inhibiting novel targets within the DNA damage response and replication stress response.” |